Although benralizumab eliminates eosinophils by binding IL-5 receptor alpha, it could not prevent the transition to the vasculitic phase because T1- and T17-related cytokines other than IL-5 are also involved in EGPA development [8]. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.